Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older at average risk. This test offers a convenient alternative for those who decline or do not complete stool-based or visual screening methods, aiming to increase screening rates among the 60 million Americans due for screening. SimpleScreen CRC detects cancer signals via circulating cell-free DNA and showed 81.1% sensitivity in clinical trials. Covered by Medicare with no out-of-pocket costs for eligible patients, Abbott also provides patient support services to help complete the screening process, with follow-up colonoscopy recommended for positive results.
Abbott Laboratories (ABT) shares are trading at USD 101.00 as of Sep 30, 2026 19:11 WIB, close to their 52-week low of USD 82.57 but well below the 52-week high of USD 134.59. Despite a modest 1-day gain of 0.06%, the stock sees more selling pressure on Pluang with 79% of orders to sell versus 21% to buy. The dividend yield stands at 2.5%, and typical investors hold the stock for about 96 days, reflecting cautious sentiment around the health sector name amid its new product launches.
Abbott will announce its financial results for the third quarter of 2026 on October 21 before the market opens. The company will host a live webcast of the earnings conference call at 8 a.m. Central time, accessible via Abbott's Investor Relations we...
Abbott Laboratories, Medtronic, and Becton Dickinson, three leading medical device companies, have each increased their dividends recently, continuing long streaks of annual raises—54 years for Abbott, 49 for Medtronic, and consistent growth for Bect...
